An observational study in Fabry Disease, Pregnancy and Pregnancy Complications, sponsored by Chiesi Farmaceutici S.p.A.. Recruiting at 5 sites in 5 countries. Open to female participants. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Chiesi Farmaceutici S.p.A. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Fabry Disease by Chiesi Farmaceutici S.p.A. — 5 open to participants now, 5 under way, 2 of them phase 3. Fabry Disease · Chiesi Farmaceutici S.p.A..
Among the 10 studies in Fabry Disease by Chiesi Farmaceutici S.p.A., this one is one of 2 that started in 2025, is one of 5 observational ones, and was the 9th registered.
244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.
Browse Fabry Disease studies →5 of the 10 studies in Fabry Disease by Chiesi Farmaceutici S.p.A. are open now, in 10 countries. Recruiting first, the newest first:
Chiesi Italia · Sites in Italy
Ages 18+
Chiesi Farmaceutici S.p.A. · Sites in United States, Austria, France and 3 more countries
Ages 2–17
Chiesi Farmaceutici S.p.A. · Sites in United States, Slovenia, United Kingdom
Ages 18+
Chiesi Farmaceutici S.p.A. · Sites in Japan
Ages 13–70
By country, each count listing its studies:
Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 4
First in 2018; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 10 is below the median of 100 across 122 observational studies indexed under Fabry Disease.
Median enrollment 26 across the 4 interventional studies, 75 across the 5 observational. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
Chiesi Farmaceutici S.p.A. is the lead sponsor of 185 studies on the registry; 22 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 11 (61%) have results posted.
1 of the studies in Fabry Disease by Chiesi Farmaceutici S.p.A. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05710692Phase 3Chiesi Farmaceutici S.p.A.Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease | 2027-10 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Fabry Disease by Chiesi Farmaceutici S.p.A., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this observational registry is to evaluate the safety and outcomes of pregnancy and lactation in women with Fabry disease who are exposed to pegunigalsidase alfa within 30 days prior to conception and/or during pregnancy and lactation.
The main objectives are to:
This is a global, decentralized, single-arm, prospective and retrospective registry planned to enroll participants over a 10-year period. Eligible patients may be enrolled by their physician or may self-enroll, where permitted by local regulations. Data will be collected through a secure web-based platform, allowing patients and physicians to enter information via electronic case report forms (eCRFs).
Pregnancy and clinical outcomes will be documented throughout pregnancy and up to 12 months post-birth. Data from self-enrolled patients will be confirmed by their primary care or attending physician. This registry is observational and does not impact clinical care or treatment decisions.
This is a global, decentralized, single-arm, prospective and retrospective observational registry designed to evaluate pregnancy and infant outcomes in women with Fabry disease who have been exposed to pegunigalsidase alfa within 30 days prior to conception and/or during pregnancy and lactation. The registry aims to assess maternal and infant safety, pregnancy outcomes, and the occurrence of congenital malformations and other neonatal conditions.
The registry will enroll patients over a 10-year period. Eligible patients may be enrolled by their physician or may self-enroll, where permitted by local regulations. Data collection will be facilitated through a secure, centralized web-based platform, where patients and physicians can enter information using electronic case report forms (eCRFs).
Enrollment \& Data Collection:
Patients can be enrolled at any time, either during pregnancy or after delivery. Depending on the timing of enrollment, data will be collected retrospectively and/or prospectively.
Pregnancy and clinical outcomes will be monitored from enrollment until the infant reaches 12 months of age.
Collected data includes maternal health, pregnancy complications, delivery outcomes, congenital malformations, and infant health parameters.
Reported congenital malformations will be classified according to established criteria (e.g., MACDP, EUROCAT) and adjudicated by an independent Scientific Advisory Committee.
The registry is observational and does not alter clinical care, physician treatment decisions, or patient management.
Pregnant and/or breastfeeding women with Fabry disease and their infants, after exposure to at least 1 dose of pegunigalsidase alfa during pregnancy and/or during lactation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female patients with Fabry disease who have been exposed to at least 1 dose of pegunigalsidase alfa at any time during pregnancy (defined as having received pegunigalsidase alfa within 30 days prior to the DOC and/or during pregnancy) and/or during lactation, and their infants.
o DOC, defined as 20/7 gestational weeks, will be calculated from last menstrual period [LMP] or ultrasound
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Not applicable- observational study
Not applicable - observational study
Pregnancy outcome: Number of live births
Time frame: at the delivery, after an average of 40 weeks of pregnancy
Pregnancy outcome: Number of preterm birth
Time frame: at delivery, prior to 37 weeks of gestation
Pregnancy outcome: Number of pregnancy losses (number of spontaneous abortions , number of pregnancy terminations, number of foetal deaths or stillbirths)
Time frame: spontaneous abortions: up to 20 weeks of pregnancy; pregnancy terminations: through the pregnancy; number of foetal deaths or stillbirths: greater than 20 weeks of pregnancy and through the pregnancy, average of 40 weeks
Number of neonates/infants with MCMs
Time frame: through the pregnancy, an average of 40 weeks and up to 12 months of infant age
Number of ectopic or molar pregnancies
Time frame: through the pregnancy, an average of 40 weeks
Number of women with obstetric and delivery complications
Time frame: at the delivery, an average of 40 weeks of pregnancy
Number of women with complications of preeclampsia or eclampsia
Time frame: through the pregnancy, an average of 40 weeks
Number of women with complications of preterm prelabour rupture of membrane
Time frame: at delivery, prior to 37 weeks of gestation
Number of neonates/infants with minor congenital malformations
Time frame: through the pregnancy, an average of 40 weeks and up to 12 months of infant age
Number of infants with developmental deficiency
Time frame: up to 12 months of infant age
Number of hospitalisations in infants
Time frame: up to 12 months of infant age
Mortality in infants, including neonatal death and infant death
Time frame: up to 12 months of infant age
Head circumference in infants (cm)
Time frame: up to 12 months of infant age
Weight in infants (kilograms)
Time frame: up to 12 months of infant age
Length in infants (cm)
Time frame: up to 12 months of infant age
Number of infants born as SGA
Time frame: up to 12 months of infant age
Number of infants with postnatal growth deficiency or FTT
Time frame: up to 12 months of infant age
Duration of breastfeeding, number of exclusively breastfeeding women and number of breastfeeding women supplemented with formula
Time frame: up to 12 months of infant age
Number of adverse events in infants exposed to pegunigalsidase alfa during breastfeeding
Time frame: up to 12 months of infant age
Started May 2025 (actual). Primary completion is estimated for Dec 2034, 115 months after the start.
Of 61 observational studies under Fabry Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 36. This study's planned 115 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.